CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease

Jing‐Yu Shao; Rong Li; Yu‐Xiang Jiao; Kai Ma; H. J. Yang; Z R Sun; Jiewen Zhang; Tao Chen

doi:10.1002/acn3.70367

March 16, 2026Annals of Clinical and Translational NeurologyOpen Access

CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to determine the relationship between CSF monoamine metabolites and cognitive decline in early Parkinson's disease.
Analysis of cerebrospinal fluid (CSF) metabolites
Longitudinal assessment of cognitive function
Assessment of baseline levels of DOPAC and HVA
Baseline CSF DOPAC levels are associated with cognitive decline
Baseline HVA levels also correlate with cognitive deterioration
Evidence suggests these metabolites can predict cognitive outcomes over time.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Findings indicate CSF DOPAC and HVA predict cognitive decline in Parkinson's disease, suggesting potential biomarkers.

Abstract

Taken together, our results indicated that baseline CSF DOPAC and HVA may serve as promising longitudinal predictors of cognitive decline in patients with PD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shao et al. (2026) studied this question.

synapsesocial.com/papers/69bb92df496e729e62980855 https://doi.org/10.1002/acn3.70367

View Full Paper

Ask AI

Bookmark

Share

CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading